Abstract:INTRODUCTION:The efficacy of chemotherapeutic agents in killing cancer cells is mainly attributed to the induction of apoptosis. However, the tremendous efforts on enhancing apoptosis-related mechanisms have only moderately improved lung cancer chemotherapy, suggesting that other cell death mechanisms such as necroptosis could be involved. In this study, we investigated the role of the necroptosis pathway in the responsiveness of nonsmall cell lung cancer (NSCLC) to chemotherapy.METHODS:In vitro cell culture and in vivo xenograft tumor therapy models and clinical sample studies are combined in studying the role of necroptosis in chemotherapy and mechanism of necroptosis suppression involving RIP3 expression regulation.RESULTS:While chemotherapeutic drugs were able to induce necroptotic cell death, this pathway was suppressed in lung cancer cells at least partly through downregulation of RIP3 expression. Ectopic RIP3 expression significantly sensitized lung cancer cells to the cytotoxicity of anticancer drugs such as cisplatin, etoposide, vincristine, and adriamycin. In addition, RIP3 suppression was associated with RIP3 promoter methylation, and demethylation partly restored RIP3 expression and increased chemotherapeutic-induced necroptotic cell death. In a xenograft tumor therapy model, ectopic RIP3 expression significantly sensitized anticancer activity of cisplatin in vivo. Furthermore, lower RIP3 expression was associated with worse chemotherapy response in NSCLC patients.CONCLUSION:Our results indicate that the necroptosis pathway is suppressed in lung cancer through RIP3 promoter methylation, and reactivating this pathway should be exploited for improving lung cancer chemotherapy.

Supplementary Table 2 from Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma

Supplementary Figure 3 from Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma

Supplemental Figure 4 from Somatic Epigenetic Silencing of <i>ripk3</i> Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma

Supplementary Figure 2 from Somatic Epigenetic Silencing of <i>ripk3</i> Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma

Supplementary Figure 7C, D from Somatic Epigenetic Silencing of <i>ripk3</i> Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma

Supplementary Figure 10 from Somatic Epigenetic Silencing of <i>ripk3</i> Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma

Supplementary Figure 1B from Somatic Epigenetic Silencing of <i>ripk3</i> Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma

Supplementary Table 1 from Survivin Expression Is Differentially Regulated by a Selective Cross-talk between RBM38 and miRNAs let-7b or miR-203a

Table S2 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Supplementary Table 2 from Survivin Expression Is Differentially Regulated by a Selective Cross-talk between RBM38 and miRNAs let-7b or miR-203a

Supplementary Table 3 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy

Supplementary Data from Autocrine IL6-Mediated Activation of the STAT3–DNMT Axis Silences the TNFα–RIP1 Necroptosis Pathway to Sustain Survival and Accumulation of Myeloid-Derived Suppressor Cells

Epigenetic Regulation of RIP3 Suppresses Necroptosis and Increases Resistance to Chemotherapy in NonSmall Cell Lung Cancer

Supplementary Table I and II from PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer

Table S1 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Table 6 from Polycomb Repressor Complex-2 is a Novel Target for Mesothelioma Therapy

Supplementary Figure 1 from Polycomb Repressor Complex-2 is a Novel Target for Mesothelioma Therapy

Supplementary Table 1 from RAGE Expression in Tumor-Associated Macrophages Promotes Angiogenesis in Glioma

Table S1 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Supplementary Table S1 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Supplementary Figure 5 from Polycomb Repressor Complex-2 is a Novel Target for Mesothelioma Therapy